Table 1.

Protocol for Active Surveillance as outlined by NICE: prostate cancer: diagnosis and treatment (CG175)

Timing	Tests
At enrolment in active surveillance	Multiparametric MRI if not previously performed
Year 1 of active surveillance	Every 3–4 months: measure PSA
	Throughout active surveillance: monitor PSA kinetics
	Every 6–12 months: DRE
	At 12 months prostate rebiopsy
Years 2–4 of active surveillance	Every 3–6 months: measure PSA
	Throughout active surveillance: monitor PSA kinetics
	Every 6–12 months: DRE
Year 5 and every year thereafter until active surveillance ends	Every 6 months: measure PSA
	Throughout active surveillance: monitor PSA kinetics
	Every 12 months: DRE